EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection

Emily Clayton, Moushimi Amaya, Dung Nguyen, Stephen M Laidlaw, Christopher C Broder, Miles Carroll

Journal of General Virology · 2026

DOI: 10.1099/jgv.0.002195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of General Virology, 2026. Verfasst von Emily Clayton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Antiviral Agents, Nipah Virus, Henipavirus Infections. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pandemic Antiviral Discovery.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nipah virus and Hendra virus are highly pathogenic henipaviruses for which there are no approved therapeutics for use in humans. Using recombinant Cedar virus expressing luciferase (rCedV-Luc) as a CL2 surrogate, we screened a library of 2,703 Food and Drug Administration (FDA)-approved compounds, yielding 5 promising candidates: bortezomib, harringtonine, homoharringtonine, ixazomib citrate and lanatoside C. Compounds demonstrated low half-maximal inhibitory concentration (IC 50 ) values of ≤0.45 µM and high selectivity indexes >6 in mammalian cell lines. Time-of-addition studies suggest that these compounds target a post-entry stage of henipavirus replication. This study demonstrates the utility of rCedV-Luc as a surrogate for the antiviral screening of henipaviruses and identification of promising candidates for further investigation and development as henipavirus antivirals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsNipah VirusHenipavirus InfectionsHumansAnimalsDrug Evaluation, PreclinicalCell LineUnited StatesVirus ReplicationUnited States Food and Drug AdministrationInhibitory Concentration 50Henipavirus

Stichwörter der Autor:innen

Cedar virusNipah virusdrug screening

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Uniformed Services University, Bethesda, MD, USA.

Förderung

  • Pandemic Antiviral Discovery

Zitieren

APA

Clayton, E., Amaya, M., Nguyen, D., Laidlaw, S. M., Broder, C. C., & Carroll, M. (2026). Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection. Journal of General Virology. https://doi.org/10.1099/jgv.0.002195

Vancouver

Clayton E, Amaya M, Nguyen D, Laidlaw SM, Broder CC, Carroll M. Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection. Journal of General Virology. 2026. doi:10.1099/jgv.0.002195

BibTeX
@article{Clayton2026,
  author = {Clayton, Emily and Amaya, Moushimi and Nguyen, Dung and Laidlaw, Stephen M and Broder, Christopher C and Carroll, Miles},
  title = {Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection},
  journal = {Journal of General Virology},
  year = {2026},
  doi = {10.1099/jgv.0.002195}
}
Kostenlos starten →